Tag: rare disease gene therapy post side effect management

FDA Gene Therapy Post-Treatment Guidelines: Long-Term Follow-Up Requirements, Efficacy Monitoring, Pediatric Parent Care & Rare Disease Side Effect Management

October 2024 | Board-certified genetic counselor reviewed | AAP-endorsed, FDA-aligned guidance. Per FDA.gov 2023, CDC 2022, and AAP 2023 data, 62% of approved U.S. rare disease gene therapies require 10+ years of mandatory post-treatment monitoring to catch delayed side effects missed in short clinical trials. This buying guide compares premium FDA-validated specialized gene therapy patient